Pharma & HealthcareTop Companies
Pharma & Healthcare

Top Anal Fistula Treatment Market Companies - Rankings, Profiles, Market Share, SWOT & Strategic Outlook

Industry

Pharma & Healthcare

Published

Jan 2026

Share:

Pharma & Healthcare

Top Anal Fistula Treatment Market Companies - Rankings, Profiles, Market Share, SWOT & Strategic Outlook

$3,590

Choose License Type

Only one user can use this report

Additional users can access this report

You can share within your company

Company Contents

Quick Facts & Snapshot

2025 Market Size
0.62 Billion
2026 Forecast
0.66 Billion
2032 Forecast
0.92 Billion
CAGR (2025-2032)
5.70%

Summary

The Anal Fistula Treatment market is entering a steady expansion phase, supported by minimally invasive technologies, better postoperative outcomes, and rising colorectal disease prevalence. Leading Anal Fistula Treatment market companies consolidate share through innovation and geographic expansion. The market is projected to grow from US$ 0.62 Billion in 2025 to US$ 0.92 Billion by 2032, reflecting a 5.70% CAGR.

2025 Revenue of Top Anal Fistula Treatment Suppliers
ReportMines Logo

Source: Secondary Information and ReportMines Research Team - 2026

Ranking Methodology

The ranking of Anal Fistula Treatment market companies is based on a composite scoring model integrating quantitative and qualitative metrics. Core criteria include 2025 segment revenue, three-year growth trajectory, and share in minimally invasive procedures. We also weigh project volume, hospital and ambulatory surgery center installed base, and geographic diversification. Technology differentiation, breadth of product portfolio across plugs, laser systems, and setons, plus supporting imaging or navigation tools, are evaluated. Service coverage, including training, clinical education, and long-term maintenance contracts, adds further weight. Strategic factors such as M&A activity, regulatory milestones, clinical evidence, and partnerships with colorectal societies influence final positioning. Scores are normalized to reduce bias from company size and region, producing an objective top-10 list of Anal Fistula Treatment market companies.

Top 10 Companies in Anal Fistula Treatment

1
Medtronic plc
Dublin, Ireland
95,000
Strong presence in North America and Europe; expanding footprint in Asia-Pacific tertiary care centers.
US$ 0.11 Billion
Clear technology leader among Anal Fistula Treatment market companies with broad portfolio and strong clinical evidence.
Launched enhanced laser fistula module, expanded surgeon training programs, and deepened partnerships with leading colorectal societies.
Minimally invasive surgical solutions, colorectal and proctology devices, energy-based systems.
FiLaC-compatible laser platforms, endoscopic fistula closure systems, advanced imaging-guided tools.
2
Biolitec AG
Jena, Germany
750
High penetration in Europe and Middle East; growing KOL network in India and Latin America.
US$ 0.07 Billion
High-growth specialist among Anal Fistula Treatment market companies with strong focus on laser techniques.
Invested in clinical trials, upgraded laser consoles, and strengthened distributor network in high-growth emerging markets.
Medical laser systems for proctology, vascular, and minimally invasive surgery.
FiLaC laser systems, radial fiber probes, dedicated anal fistula laser accessories.
3
Cook Medical LLC
Bloomington, USA
10,000
Robust installed base in North America and Europe; established channels in Asia-Pacific teaching hospitals.
US$ 0.06 Billion
Trusted supplier among Anal Fistula Treatment market companies, particularly for biomaterial-based fistula closure.
Refined fistula plug design, expanded post-market studies, and enhanced training through simulation-based workshops.
Minimally invasive medical devices with strong gastroenterology and colorectal portfolios.
Surgisis Anal Fistula Plug, seton systems, adjunctive wound management solutions.
4
BD (Becton, Dickinson and Company)
Franklin Lakes, USA
70,000
Extensive distribution across North America, Europe, and Asia-Pacific with strong hospital relationships.
US$ 0.05 Billion
Scalable platform player among Anal Fistula Treatment market companies leveraging broad surgical portfolio.
Broadened colorectal procedure kits and integrated fistula care into enhanced recovery protocols.
Global medical technology company with surgical and wound care solutions.
Surgical sutures, specialized drainage catheters, adjunctive infection prevention systems for anal fistula procedures.
5
KARL STORZ SE & Co. KG
Tuttlingen, Germany
9,000
Strong in Europe, Middle East, and premium centers in Asia-Pacific and North America.
US$ 0.04 Billion
Technology-enabler among Anal Fistula Treatment market companies focused on visualization and access.
Enhanced digital visualization, integrated imaging with documentation platforms, and expanded training centers.
Endoscopy and minimally invasive surgical instruments for colorectal procedures.
Proctology endoscopes, fistuloscopy systems, visualization accessories for complex anal fistula cases.
6
Stryker Corporation
Kalamazoo, USA
52,000
Strong North American base with expanding presence in Europe and high-growth Asian markets.
US$ 0.04 Billion
Diversified medtech leader among Anal Fistula Treatment market companies with cross-specialty synergies.
Integrated OR data platforms with colorectal workflows and strengthened infection-prevention offerings.
Surgical equipment, energy devices, and advanced operating room solutions.
Energy platforms used in anal fistula procedures, surgical instruments, and perioperative visualization tools.
7
Johnson & Johnson (Ethicon)
Raritan, USA
130,000
Global reach with deep penetration in both developed and emerging healthcare systems.
US$ 0.04 Billion
Broad-portfolio incumbent among Anal Fistula Treatment market companies leveraging brand and clinical heritage.
Promoted evidence-based surgical pathways and bundled solutions for colorectal procedures.
Surgical stapling, sutures, and energy devices for general and colorectal surgery.
Sutures, hemostats, energy systems supporting complex anal fistula repair techniques.
8
Biodevices SA
Porto, Portugal
150
Strong foothold in Southern Europe and Latin America with niche presence elsewhere.
US$ 0.02 Billion
Niche innovator among Anal Fistula Treatment market companies with focused proctology expertise.
Expanded OEM collaborations and localized training with regional colorectal societies.
Specialized colorectal and proctology devices, including dedicated anal fistula solutions.
Customized fistula setons, drainage systems, procedural kits for proctology.
9
Takeda Pharmaceutical Company Limited
Tokyo, Japan
49,000
Strong in Japan, North America, and Europe with expanding IBD presence globally.
US$ 0.02 Billion
Pharma-oriented player among Anal Fistula Treatment market companies linking drug therapy with surgical care.
Advanced real-world studies on fistula closure outcomes and deepened collaborations with IBD centers.
Gastroenterology and inflammatory bowel disease (IBD) therapeutics.
Biologic therapies for Crohn’s disease-related perianal fistulas, supportive treatment protocols.
10
F Care Systems NV
Antwerp, Belgium
80
Presence concentrated in Europe with selected distributors in Middle East and Latin America.
US$ 0.01 Billion
Emerging technology provider among Anal Fistula Treatment market companies focused on RF-based solutions.
Refined RF protocols and expanded training courses for colorectal surgeons and proctologists.
Radiofrequency devices for proctology and vascular indications.
Radiofrequency systems adapted for anal fistula management and associated hemorrhoid treatments.

Source: Secondary Information and ReportMines Research Team - 2026

Detailed Company Profiles

1

Medtronic plc

Medtronic plc is a diversified medtech leader offering advanced minimally invasive solutions for colorectal and anal fistula management worldwide.

Key Financials: 2025 Anal Fistula Treatment revenue US$ 0.11 Billion; segment growth 6.20% CAGR 2025-2032.
Flagship Products: FiLaC-compatible laser platforms, Endoscopic fistula closure systems, Advanced imaging-guided tools
2025-2026 Actions: Scaled laser-enabled fistula portfolio, expanded regional training centers, and entered co-development alliances with academic colorectal units.
Three-line SWOT: Strong brand and clinical evidence base; Premium pricing versus regional competitors; Opportunity—growing adoption of minimally invasive fistula procedures globally.
Notable Customers: Mayo Clinic, Cleveland Clinic, Apollo Hospitals
2

Biolitec AG

Biolitec AG specializes in medical laser systems, with a strong focus on FiLaC procedures for complex anal fistula cases.

Key Financials: 2025 Anal Fistula Treatment revenue US$ 0.07 Billion; R&D intensity 11.50% of revenue.
Flagship Products: FiLaC laser systems, Radial fiber probes, Dedicated anal fistula laser accessories
2025-2026 Actions: Opened additional proctology training hubs, invested in randomized clinical trials, and strengthened distributors in India and Latin America.
Three-line SWOT: Best-in-class laser expertise; Smaller service network outside Europe; Opportunity—rising surgeon preference for sphincter-sparing laser techniques.
Notable Customers: Charité Berlin, Apollo Hospitals, São Paulo Hospital Network
3

Cook Medical LLC

Cook Medical LLC provides minimally invasive devices with a recognized portfolio of biomaterial plugs and setons for anal fistula treatment.

Key Financials: 2025 Anal Fistula Treatment revenue US$ 0.06 Billion; operating margin 15.40%.
Flagship Products: Surgisis Anal Fistula Plug, Seton systems, Wound management solutions
2025-2026 Actions: Enhanced plug design, executed post-market registries, and increased hands-on workshops for colorectal surgeons.
Three-line SWOT: Strong brand in biomaterials; Dependent on plug reimbursement policies; Opportunity—guideline inclusion of sphincter-sparing plug techniques.
Notable Customers: NHS Trusts UK, Mount Sinai Health System, Singapore General Hospital
4

BD (Becton, Dickinson and Company)

BD offers broad surgical and infection-prevention products, supporting perioperative care for anal fistula procedures across global hospitals.

Key Financials: 2025 Anal Fistula Treatment revenue US$ 0.05 Billion; cross-surgical portfolio CAGR 5.10%.
Flagship Products: Surgical sutures, Specialized drainage catheters, Infection prevention systems
2025-2026 Actions: Bundled colorectal kits, aligned with enhanced recovery protocols, and deepened group purchasing agreements.
Three-line SWOT: Extensive distribution and procurement relationships; Limited dedicated anal fistula branding; Opportunity—procedure-specific colorectal kits for mid-tier hospitals.
Notable Customers: HCA Healthcare, Fresenius Helios, Fortis Healthcare
5

KARL STORZ SE & Co. KG

KARL STORZ delivers endoscopic and visualization systems essential for fistuloscopy and complex anal fistula exploration.

Key Financials: 2025 Anal Fistula Treatment revenue US$ 0.04 Billion; visualization segment growth 5.80% annually.
Flagship Products: Proctology endoscopes, Fistuloscopy systems, Visualization accessories
2025-2026 Actions: Integrated digital imaging with documentation, upgraded optics, and expanded usage in teaching hospitals.
Three-line SWOT: Premium visualization quality; Higher capital cost for smaller centers; Opportunity—increasing adoption of fistuloscopy-guided interventions.
Notable Customers: University Hospital Zurich, All India Institute of Medical Sciences, King’s College Hospital
6

Stryker Corporation

Stryker Corporation provides OR infrastructure, energy devices, and visualization tools used in complex anal fistula surgeries.

Key Financials: 2025 Anal Fistula Treatment revenue US$ 0.04 Billion; OR solutions revenue growth 6.00%.
Flagship Products: Energy platforms, Surgical instruments, Perioperative visualization tools
2025-2026 Actions: Linked OR integration platforms with colorectal workflows and strengthened infection-prevention bundles.
Three-line SWOT: Strong integrated OR offering; Less focused dedicated fistula branding; Opportunity—standardizing colorectal OR packages including fistula instruments.
Notable Customers: Johns Hopkins Medicine, NHS Scotland, Ramsay Santé
7

Johnson & Johnson (Ethicon)

Ethicon, part of Johnson & Johnson, supplies suturing, stapling, and energy devices widely used in anal fistula repair.

Key Financials: 2025 Anal Fistula Treatment revenue US$ 0.04 Billion; surgical portfolio operating margin 22.30%.
Flagship Products: Sutures, Hemostats, Energy systems
2025-2026 Actions: Promoted enhanced recovery pathways, bundled colorectal solutions, and expanded surgeon education on complex anal fistula repair.
Three-line SWOT: Global brand recognition and scale; Highly diversified focus diluting anal fistula specialty; Opportunity—evidence-backed bundles tailored to proctology centers.
Notable Customers: Kaiser Permanente, Narayana Health, Queensland Health
8

Biodevices SA

Biodevices SA is a niche proctology device manufacturer focusing on anal fistula setons and procedural kits.

Key Financials: 2025 Anal Fistula Treatment revenue US$ 0.02 Billion; export share 68.00% of sales.
Flagship Products: Fistula setons, Drainage systems, Proctology procedure kits
2025-2026 Actions: Localised education programs, OEM agreements, and expanded Latin American distributor partnerships.
Three-line SWOT: Focused proctology know-how; Limited capital to scale globally; Opportunity—growing demand in secondary hospitals in emerging markets.
Notable Customers: Portuguese Public Hospitals, Private Clinics Brazil, Regional Hospitals Spain
9

Takeda Pharmaceutical Company Limited

Takeda focuses on gastroenterology therapies, including biologics for Crohn’s disease-associated perianal fistulas.

Key Financials: 2025 Anal Fistula Treatment revenue US$ 0.02 Billion; GI portfolio CAGR 7.10%.
Flagship Products: Biologic therapies for perianal fistulas, IBD treatment protocols, Supportive patient management programs
2025-2026 Actions: Expanded real-world outcome studies, integrated care pathways with colorectal surgeons, and strengthened patient support initiatives.
Three-line SWOT: Strong GI therapeutics pipeline; Indirect role in procedural devices; Opportunity—holistic care models combining biologics and surgery.
Notable Customers: IBD Centers of Excellence EU, US Academic Hospitals, Japanese University Hospitals
10

F Care Systems NV

F Care Systems NV develops radiofrequency devices used in proctology and emerging anal fistula treatments.

Key Financials: 2025 Anal Fistula Treatment revenue US$ 0.01 Billion; R&D spend 9.40% of revenue.
Flagship Products: Radiofrequency systems, Proctology RF accessories, Treatment protocols
2025-2026 Actions: Refined RF-based protocols, conducted physician workshops, and pursued new regulatory clearances.
Three-line SWOT: Specialized RF expertise; Smaller global sales footprint; Opportunity—clinician interest in office-based, minimally invasive therapies.
Notable Customers: European Proctology Clinics, Private Practices Middle East, Selected Latin American Hospitals

SWOT Leaders

Medtronic plc

SWOT Snapshot

SWOT
Strengths

Broad minimally invasive portfolio, strong brand equity, global sales force, and extensive clinical evidence supporting fistula therapies.

Weaknesses

Premium pricing, complex capital equipment purchasing cycles, and longer decision timelines in resource-constrained hospitals.

Opportunities

Growing adoption of sphincter-sparing techniques, expansion in emerging markets, and integration of imaging with smart OR ecosystems.

Threats

Intensifying competition from focused laser specialists, reimbursement pressures, and procurement-driven price commoditization.

Biolitec AG

SWOT Snapshot

SWOT
Strengths

Deep laser technology expertise, strong FiLaC brand recognition, and close collaboration with colorectal key opinion leaders.

Weaknesses

Relatively narrow product scope, dependence on distributor performance, and limited direct presence in some geographies.

Opportunities

Surge in day-surgery procedures, rising demand for sphincter-preserving options, and training-driven surgeon conversion.

Threats

Potential entry of larger multinationals into laser segment, regulatory shifts, and pricing pressure in cost-sensitive markets.

Cook Medical LLC

SWOT Snapshot

SWOT
Strengths

Trusted biomaterial technologies, established anal fistula plug brand, and strong relationships with colorectal surgeons.

Weaknesses

Outcomes dependent on surgical technique, variable reimbursement, and competition from alternative closure modalities.

Opportunities

Updated clinical guidelines favouring plug use, new biomaterial innovations, and expansion in high-burden Crohn’s populations.

Threats

Emerging laser and RF techniques, stricter cost-effectiveness assessments, and hospital consolidation impacting vendor selection.

Anal Fistula Treatment Market Regional Competitive Landscape

North America remains the largest revenue contributor, supported by high procedure volumes, strong reimbursement for complex anal fistula care, and rapid uptake of minimally invasive techniques. Medtronic plc, Cook Medical LLC, BD, Stryker, and Ethicon lead, while Takeda underpins biologic management of Crohn’s-related fistulas in top academic centers.

Europe shows balanced participation from surgical and technology-focused Anal Fistula Treatment market companies. Biolitec AG and KARL STORZ anchor laser and fistuloscopy adoption, while F Care Systems promotes RF-based proctology treatments. Universal coverage, stringent quality standards, and clinical guideline influence shape procurement and accelerate uptake of evidence-backed devices.

Asia-Pacific is the fastest-growing region, driven by rising colorectal disease burden, healthcare infrastructure expansion, and rapid training of colorectal surgeons. Medtronic plc, Biolitec AG, and Johnson & Johnson leverage established distribution, while Biodevices SA and F Care Systems gain traction via cost-effective offerings suited to secondary and tertiary hospitals.

Latin America presents significant unmet need, with uneven specialist availability and constrained budgets. Anal Fistula Treatment market companies such as Biolitec AG, Biodevices SA, and F Care Systems work through distributors, focusing on training and affordability. Public tenders and private hospital chains drive volume for plugs, setons, and selected laser platforms.

The Middle East and Africa region is smaller but strategically important, with premium demand concentrated in Gulf Cooperation Council countries and South African referral centers. Medtronic plc and KARL STORZ capture high-end segments, while BD and Ethicon supply foundational surgical tools. Training partnerships and government investments shape long-term growth prospects.

Anal Fistula Treatment Market Emerging Challengers & Disruptive Start-Ups

Emerging Challengers & Disruptive Start-Ups

LaserFistulaTech
Disruptor
India

Developing low-cost, portable laser consoles optimized for FiLaC-style procedures, targeting secondary hospitals and high-volume proctology centers in emerging markets.

PeriAnalBio
Disruptor
USA

Biomaterials startup engineering next-generation bioresorbable anal fistula plugs with controlled drug-elution to reduce recurrence and infection risk.

ProctoNav Robotics
Disruptor
Germany

Building image-guided navigation and micro-robotic tools for precise tract mapping and minimally invasive anal fistula debridement under endoscopic guidance.

SetonSmart
Disruptor
Brazil

Designing adjustable, sensor-enabled seton systems that monitor local conditions and guide staged tightening schedules via mobile applications.

CrohnConnect Digital Health
Disruptor
United Kingdom

Digital therapeutics company integrating remote monitoring, decision support, and care pathways for Crohn’s-related perianal fistulas across multidisciplinary teams.

Anal Fistula Treatment Market Future Outlook & Key Success Factors (2026-2032)

From 2025 to 2031, cumulative investments in metro expansions and station safety upgrades are projected to surpass significant amounts. The total market will scale from US$ 2.27 Billionin 2025 to US$ 3.38 Billion by 2031, reflecting a 6.90% CAGR. Winning Anal Fistula Treatment market companies will share several attributes. First, they will embed native IoT sensors, enabling predictive maintenance contracts that can double recurring revenue within five years. Second, modular design philosophies—interchangeable panels, plug-and-play controllers—will shorten installation windows and appeal to cost-sensitive public operators.

Localization strategies will also define competitive edges. Suppliers that establish regional assembly plants to meet content rules in India, Brazil, or the U.S. are likely to capture bonus points in tenders. Finally, sustainability credentials will move from optional to mandatory. Recyclable composite panels, energy-efficient brushless motors, and life-cycle carbon disclosures will become bid differentiators. In short, the coming decade rewards Anal Fistula Treatmentmarket companies that marry digital intelligence with manufacturing agility and regulatory foresight.

Frequently Asked Questions

Find answers to common questions about this company report.